particularly the endemic liver flukes such as Opisthorchis viverrini, is a major epidemiological factor for CCA. 4 
| DRIVE R GENE LANDSCAPE IN THE LARGEST HCC COHORT
Several landmark studies of WES and WGS, including those from the International Cancer Genome Consortium and TCGA, have already analyzed large-scale cohorts of HCC in different epidemiological and ethnic backgrounds. [5] [6] [7] [8] At present, genomic data from more than 1000 HCC cases are publicly available. We compiled these data from four previous studies that included 1340 cases from different ethnic groups, including 642 cases from a Japanese cohort, 451 cases from TCGA, and 247 cases from a French cohort (Table S1 ). Using the largest HCC cohort ever reported, we attempted to identify driver genes that could evaluate the most precise frequencies of mutations in HCC. We defined a driver gene as a statistically significantly mutated gene after adjusting the background mutation rate (Appendix S1). Thirty-three significantly mutated driver genes (q-value < 0.1; Table S2 ) are listed in Figure 1 . The two most frequently mutated genes were TP53 (29.1% of total cases) and CTNNB1 (28.6%). WNT signaling regulates cell proliferation, stem cell maintenance, and other oncogenic signals, and CTNNB1 plays a central role in activating WNT signaling. Previous sequencing analyses of different ethnic groups reported that these two genes were the most frequent, confirming that they are master driver genes of HCC beyond the diversities of ethnic/epidemiological backgrounds.
Telomerase reverse transcriptase restores telomere length during replication, and is required for cell transformation or escaping from senescence. Recently, TPMs were reported in a broad range of human cancers including HCC. 9 Because TPMs were analyzed in part by studies we compiled (TPMs were analyzed in 1093
cases) and are difficult to be precisely identified by Illumina sequencing due to their presence in the highly GC rich genome area, the true frequencies of TPMs could not be established in the current study. However, four large-scale studies reported highly frequent TPMs (>50%) in Japanese, French, and US (TCGA) cohorts, 5, [7] [8] [9] [10] suggesting that TERT also belongs to the master HCC driver genes. TERT promoter mutations are reported to occur in dysplastic nodules or early HCC, suggesting that TPMs could be founding driver genes in HCC. 11 Chiba et al 12 reported that
TPMs have a two-step mechanism in cell transformation: promoting immortalization in the initial phase, and induction of genomic instability in the later stage. Collectively TP53, CTNNB1 (WNT signal), and TERT (immortalization) are the core driver genes in HCC of all ethnic groups ( Figure 2A ). Therefore, its inactivation is largely complimentary to CTNNB1 activating mutations for WNT signal activation in HCC. 15 In contract to these well-characterized tumor suppressor genes, the biological roles of highly frequent mutations of ALB and APOB in HCC are uncertain.
Because both ALB and APOB mutations were strongly enriched in indels, these indels could be caused by replication slippage errors and may result from conflicts between the replication and transcription machineries.
16
F I G U R E 1 Frequencies of significantly mutated driver genes in 1340 hepatocellular carcinoma genomes. Genes were sorted by q-value. Somatic mutations in the coding exons of 1340 hepatocellular carcinoma genomes were accumulated and the statistical significance of mutation frequencies in driver genes were estimated. Briefly, the P-values from each individual significance test were calculated as the geometric mean, as previously reported. 5 Multiple testing adjustments (q-value) were carried out as described. 45 Note that the frequency of TERT promoter mutations was calculated by combining data from four studies 5,7-9 SHIBATA ET AL.
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The remaining top driver genes were mutated in a fraction of cases (<5%) with various biological functions ( Figure 2A ). CDKN2A, RB1, and CCND1 regulated cell cycle checkpoints, whereas RPS6KA3, PTEN, PIK3CA, and TSC2 are implicated in growth factor signaling and the mTOR pathway. EEF1A1 encodes the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome, which has oncogenic and invasive activities. 17 They also include therapeutic targets such as PIK3CA, PTEN, and CCND1. These infrequently mutated driver genes might contribute to specific cellular phenotypes such as aggressive growth, invasiveness, or metastasis. Alternatively, combined with other types of alterations or alterations of other genes involved in the same functional pathways, they could play more major roles in HCC.
There are little data regarding non-coding driver genes in HCC.
Fujimoto et al 7 reported the largest WGS of 300 Japanese cases of HCC and identified recurrent non-coding mutations. They found that TPM was the most frequent and significant mutation, followed by NEAT1 and MALAT1, both of which are non-coding RNAs.
| STRUCTURAL REARRAN GEMENTS AN D VIRUS INTEGRATION IN H CC
Copy number alterations and structural rearrangements occur frequently in HCC. [5] [6] [7] [8] Although rare, chromothripsis was also reported in HCC. 7 A broad range of cancer-related genes including oncogenes F I G U R E 2 Landscapes of major driver genes in hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). A, Combination of three core driver genes (TP53, TERT, and WNT signal) and other driver pathways in HCC. B, Combination of five core driver genes (TP53, ARID1A, KRAS, SMAD4, and BAP1) and other driver pathways in BTC. TGFb, transforming growth factor-b (including MYC, TERT, CCND1, and MET) and tumor suppressor genes (including TP53, RB1, ARID1A, CDKN2A, and APC) were affected by these molecular events. 5, 7, 8 In addition to somatic rearrangements, HBV genome integration also affects gene expression in HCC.
Recurrent targets of HBV integration include TERT, MLL4, and CCNE1, and their expressions were elevated by virus genome integrations. 18, 19 Copy number alterations were also significantly increased at HBV breakpoint locations, implying that HBV genome integration was associated with chromosomal instability. 18, 19 Three groups reported integration of the AAV2 genome in HCC. 7, 20, 21 Integrations of the AAV2 genome were detected 5.7% of French HCC cases. 20 It was reported that AAV2-positive tumors tended to occur in non-cirrhotic liver without known risk factors, suggesting that AAV2 genome integration might play an oncogenic role in some of the cases currently classified as risk-free. Integration of AAV2 was reported to be rarer (~1%) in Japanese (3/300) and Korean (2/289) cohorts. 
| DRIVE R GENE LANDSCAPE OF BTC
Nakamura et al 25 reported the first large-scale WES and transcriptome sequencing of 260 BTC cases that contained three anatomical subtypes (145 ICC cases, 86 ECC cases, and 29 GB cases). Three top diver genes were TP53 (26% of all cases), KRAS (18%), and ARID1A (11%), followed by SMAD4, BAP1, PIK3CA, ARID2, and GNAS. Similar to HCC, most driver genes were altered in a fraction (<5%) of cases, suggesting of genetic heterogeneity in BTC. TERT promoter mutations were detected in 21% of GB cases, whereas only one ICC case had these mutations. This is quite a contrast with the high frequency of TPMs in HCC as described above.
The list of frequently mutated driver genes in BTC cases looks partly similar to that of HCC (TP53, ARID1A, and ARID2) and pancreatic cancer (TP53, KRAS, and SMAD4) (Figure 4) . By contrast, characteristically, alterations in WNT signaling and TERT were infrequent and IDH1 mutations (3%) were unique in BTC. Nakamura et al further classified driver genes among anatomical subtypes, and reported subtype-specific and shared driver genes (Figure 4 ). For example, IDH1 and BAP1 mutations were ICC-specific, whereas ELF3 and ARID1B mutations were more common in ECC. EGFR, ERBB2, PTEN, and ARID2 mutations with TPMs occurred more frequently in GB cases. The molecular mechanisms underlying the selection of specific driver genes along anatomical locations and characteristic differences between HCC and ICC remain completely unknown. It could be possible that cell type-specific expression levels or signaling cascades, or carcinogenic causes, might affect the selection of driver genes.
Whole genome sequencing of liver cancer displaying biliary phenotypes revealed a mixture genetic profiles of HCC and ICC, suggesting that this category could be a marginal mixture of two tumor types. 26 Activation or inactivation of some driver genes might exert cytotoxicity or a differentiation switch in specific lineages of liver and bile duct cancer, as reported in the case of IDH1 mutations. 27 The Cancer Genome Atlas CCA project analyzed 34 CCA samples that were fluke-negative and HBV/HCV-negative. 28 Due to the limited size of the cohort, frequencies of driver genes were variable compared to other large-scale studies; however, notably, this cohort F I G U R E 4 Specific driver genes across anatomical subtypes of biliary tract cancer (BTC), and comparison with core driver genes in hepatocellular carcinoma (HCC) and pancreatic cancer. ECC, extrahepatic cholangiocarcinoma; GB, gallbladder cancer; ICC, intrahepatic cholangiocarcinoma represented a higher frequency of IDH1 (13%) and IDH2 (5%) mutations compared to Asian cohorts. Other studies also reported high frequencies of IDH1/2 mutations in Caucasian CCA cases, 29 suggesting that IDH1/2 could be ethnic-preferential driver genes in BTC.
The CCA cells with IDH1 mutations were reported to be more sensitive to a multikinase inhibitor dasatinib. 30 Jusakul et al 31 There are limited genomic data of GB cancers. Li et al 32 reported
WES of 57 Chinese GB samples. TP53 (47.1%), ERBB3 (11.8%), and KRAS (7.8%) were the top three driver genes, and ErbB signaling (including EGFR, ERBB2, ERBB3, and ERBB4 and their downstream genes) was the most extensively mutated pathway. These observations were consistent with the above report of a Japanese cohort. 32 Whole transcriptome sequencing revealed fusion genes in CCA.
Among them, fusion genes containing FGFR2 tyrosine kinase and cyclic AMP-dependent PKA signaling components (PRKACA and PRKACB) they are recurrently reported in previous papers and they are also therapeutic targets. 25, 31 The FGFR2 fusion genes were gen- showed that kinase inhibitors targeting FGFR2 could be effective for these kinase fusion genes, [35] [36] [37] and clinical trials of several FGFR2
inhibitors are ongoing. The response rate of a recent phase II clinical trial was 18.8% for FGFR2 fusion-positive CCA, 38 and acquired resistant secondary FGFR2 mutations have been identified. 39 Clinical features of FGFR2 fusion-positive CCA remain unclear, however, flukepositive CCA was reported to be negative for FGFR2 fusion genes.
31
F I G U R E 5 Diverse fusion partners with FGFR2 reported in biliary tract cancer. Nineteen fusion partner genes with FGFR2 identified so far are shown with structural rearrangements. References are listed in Table S3 6 | MOLECULAR CARCINOGENESIS OF BTC (FIGURE 3) Recently, an outbreak of CCA was reported among workers in an offset color proof-printing company in Japan. 40 These cases had These unique mutation spectra could be useful for understanding carcinogenesis processes by these chemicals and evaluating chemical exposure and screening.
| INTEGRATIVE MOLECULAR CLASSIFICATION OF HEPATOBILIARY CANCER (FIGURE 6)
Integrating genome data (mutation, copy number, fusion gene, and mutational signature) with transcriptome, epigenome, proteome, and metabolome data will contribute to identifying unique molecular subtypes in cancer.
The Cancer Genome Atlas HCC group assembled the largest collection of genome, transcriptome, epigenome, and proteome data in 196 HCC cases. 8 By integrating these omics data, they identified three subclasses (iClust 1-3). These clusters partly overlapped with the gene expression-based subtypes (S1-3) reported by Hoshida et al. 43 Tumors in iClust 1 tended to have lower frequency of CTNNB1 mutation, TPMs, and CDKN2A silencing, whereas iClust3 was characterized by a higher degree of chromosomal instability with high frequency of TP53 mutation and CpG hypomethylation. By comparing expression signatures in these subtypes, they found significant similarity between HCC-C1 and ICC-C1 (common C1), and HCC-C2 and ICC-C2 (common C2). Genes highly expressed in common C1 tumors were enriched with mitotic checkpoint signaling pathway and Hoshida's S1-2-related genes, whereas common C2 tumors tended to express more cell immunity-related pathway. They further collected molecular data of 847 liver cancers (561 HCC and 286 ICC, 582 Asian and 265 Caucasian), and found that C1/C2 clusters were reproducible in Asian samples but were less stable in Caucasian cases.
Transcriptome sequencing and WES of 160 Japanese BTC identified four BTC subtypes (Nakamura clusters 1-4), that were associated with prognosis and specific driver gene profiles. 25 Nakamura cluster 3 was enriched with IDH1, BAP1, and NRAS mutations and FGFR2 fusion genes, but rarely harbored TP53, KRAS, and SMAD4
mutations. This cluster partly overlaps to the UM subtype identified in the above study, 44 which was enriched in IDH1 and BAP1 mutations. Nakamura cluster 4 showed higher immune checkpoint activity and was enriched with hypermutated and more neo-antigen-presenting cases, suggesting immune evasion processes were more active in this subtype.
Integration of genome, transcriptome, and epigenome data from 95 CCA cases revealed four subtypes (CCA clusters 1-4) that were associated with the presence of liver fluke infection and prognosis. 
